On December 16, the FDA released an updated “Post-Marketing Adverse Events Summary.” The report also states that "The estimated number of women who have used mifepristone in the U.S. for medical termination of pregnancy through the end of June 2021 is approximately 4.9 million women."
All "successful" chemical abortions end in the death of an innocent unborn child. They also pose a substantial risk, however, to women who have ectopic pregnancies or take the pill after 10 weeks gestation.
The FDA's summary also noted that mifepristone (the first pill in the abortion pill regimen) has been linked to 4,207 instances of adverse effects. These included 1,045 hospitalizations and 603 times that women lost so much blood that they needed transfusions. The FDA report also showed 413 instances where women who had taken the pill had infections. 70 of those infections were categorized as "severe."
These almost certainly undershoot the total number of abortions and adverse effects. There are no national requirements that abortionists report complications. The Charlotte Lozier Institute wrote that “an analysis of the data collected under this reporting requirement suggests that a significant number of complications were unreported and that the FDA may have missed as many as 95% of serious chemical abortion adverse events.”